Is anemia a marker of advanced disease or a therapeutic target in heart failure?;La anemia en la insuficiencia cardíaca. ¿Es un marcador de gravedad o un objetivo terapéutico?

Revista Espanola de Cardiologia

Volumn 58, Issue 1, 2005, Pages 10-12

  Roig Mingell, Eulalia ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; NEUROHORMONE; RECOMBINANT ERYTHROPOIETIN; TUMOR NECROSIS FACTOR ALPHA;

ANALYSIS OF VARIANCE; ANEMIA; CLINICAL FEATURE; COMORBIDITY; CORRELATION ANALYSIS; DISEASE SEVERITY; EDITORIAL; HEART FAILURE; HEART VENTRICLE FUNCTION; HEMOGLOBIN DETERMINATION; HOSPITALIZATION; HUMAN; HYPERTENSION; MORTALITY; OXYGENATION; PREVALENCE; PROGNOSIS; THROMBOSIS;

EID: 14944375376     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13070502     Document Type: Editorial

References (17)

1. Rodríguez Artalejo F, Banegas Banegas JR, Guallar-Castillón P. Epidemología de la insuficiencia cardíaca. Rev Esp Cardiol. 2004;57:163-70.
2. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomized trial. Lancet. 1999;353:9-13.
3. Pfeffer MA, McMurriay J, Velásquez EJ, Rouleau JL, Kober L, Maggioni AP, et al, for the Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-906.
4. Wong M, Staszewsky L, Latini R, Barlera S, Glazer R, Aknay N, et al. Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: valsartan heart failure trial (Val-HeFT) echocardiographic data. J Am Coll Cardiol. 2004;43:2022-7.
5. Cohn JN, Ferrari R, Saharpe N. Cardiac remodeling: concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol. 2000;35:569-82.
6. Tanner H, Moschovitis G, Kuster GM, Hullin R, Pfiiffner D, Hess OM, et al. The prevalence of anemia in chronic heart failure. Int J Cardiol. 2002;86:115-21.
7. Komajda M. Prevalence of anemia in patients with chronic heart failure and their clinical characteristics. J Card Fail. 2004;10:S1-4.
8. Lupón J, Urrutia A, González B, Herreros J, Altimir S, Coll R, et al. Significado pronóstico de los valores de hemoglobina en pacientes con insuficiencia cardíaca. Rev Esp Cardiol. 2005;58: 48-53.
9. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Borenstein J. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol. 2002;39:1780-6.
10. Kosborod M, Smith GL, Radford MJ, Foody JM, Krumholz HM. The prognostic importance of anemia in patients with heart failure. Am J Med. 2003; 114:112-9.
11. Mozaffarian D, Nye R, Levy WC. Anemia predicts mortality severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE). J Am Coll Cardiol. 2003;41:1933-9.
12. Hussein SJ, Jain R, Shlipak MG, Ansari M, Massie BM. Chronic heart failure is not an independent cause of anemia. J Card Fail. 2003;9:19-22.
13. Felker GM, Adams KF Jr, Gattis WA, O'Connor CM. Anemia as a risk factor and therapeutic target in heart failure. J Am Coll Cardiol. 2004;44:959-66.
14. Kalra PR, Bolger AP, Francis DP, Genth-Zotz S, Sharma R, Ponikowski PP, et al. Effect of anemia on exercise tolerance in chronic heart failure in men. Am J Cardiol. 2003;91:888-91.
15. Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 2000;35:1737-44.
16. Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation. 2003;107:294-9.
17. Taylor JE, McLaren M, Henderson IS, Belch JJ, Stewart WK. Prothrombotic effect of erythropoietin in dialysis patients. Nephrol Dial Transplant. 1992;7:235-9.